

PATIENT INFORMATION:

Patient Name: _____ DOB: _____ Phone: _____

Patient Status: ☐ New to Therapy ☐ Continuing Therapy **Next Treatment Date:** _____

DIAGNOSIS AND ICD-10 CODE:

Diagnosis: Multiple Sclerosis **ICD-10 Code:** G35

Type: ☐ Relapsing-Remitting ☐ Primary-Progressive ☐ Secondary-Progressive ☐ Clinically Isolated

Weight: _____ lbs Allergies: _____

PRESCRIPTION:

Ocrevus (ocrelizumab) IV:

☐ **Initial start:** 300mg IV at 0 and 2 weeks, then 600mg IV every 6 months x 1 year

☐ 600mg IV every 6 months x 1 year

Protocol IV Pre-medication Orders: Solu-Medrol 100mg IV and diphenhydramine 25mg PO
30 minutes before infusion

Substitute diphenhydramine with: ☐ Loratadine 10mg PO ☐ Cetirizine 10mg PO
☐ Cetirizine 10mg IV

Ocrevus Zunovo (ocrelizumab/hyaluronidase):

☐ 920mg/23,000units subcutaneously every 6 months x 1 year

Protocol SubQ Pre-medication Orders: dexamethasone 20mg PO & cetirizine 10mg PO
30 minutes before injection

Lab Orders: _____ **Lab Frequency:** _____

Other orders: _____

US Infusions will follow office protocol for anaphylaxis.

PROVIDER INFORMATION:

By signing this form, you authorize US Infusions and its staff to handle prior authorizations, coordinate with insurance providers, and determine the patient's preferred site of care.

Provider Name: _____ Signature: _____ Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

****PLEASE COMPLETE BOTH SIDES OF THIS FORM****

PATIENT INFORMATION:

Patient Name: _____ DOB: _____

PLEASE INCLUDE DOCUMENTATION BELOW FOR PRIOR AUTHORIZATION:

- ☐ signed and completed order (MD/prescriber to complete page 1)
- ☐ Patient demographic information and insurance information
- ☐ Patient's medication list
- ☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to therapy
 - ☐ Expanded Disability Status Scale (EDSS) score: _____
- ☐ Include labs and/or test results to support diagnosis
 - ☐ MRI
- ☐ *If applicable* - Last known biological therapy: _____ and last date received: _____
If patient is switching to biologic therapies, please perform a wash-out period of _____ weeks prior to starting ocrelizumab.
- ☐ Other medical necessity: _____

REQUIRED PRE-SCREENING:

- ☐ **Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) - attach results**
 - ☐ **Positive** ☐ **Negative**

*If Hepatitis B results are positive - please provide documentation of treatment or medical clearance